Julian K. Horwitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julian K. Horwitz has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Vatche G. Agopian
Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
1 shared publication
Latest Publications
- Open Access
- 22 February 2024
- Published by Springer Nature in Current Hepatology Reports
- Vol. 23 (1) , 185-192
Indication of Liver Transplant for HCC: Current Status and Future Directions
Purpose of Review: Liver transplantation remains the gold-standard treatment for cirrhotic patients with early stage, surgically unresectable hepatocellular carcinoma (HCC). In this review, we describe the current state of liver transplantation (LT) for HCC. Recent Findings: We review recent advances in expanded indications for LT, diagnostics with liquid biopsy and biomarkers, and the emerging role of immunotherapy in this patient population. Summary: Although the shortage of liver allografts necessitates a restrictive HCC selection policy, future advances in patient selection, liquid biopsy technologies and systemic therapies have the potential to improve access to liver transplantation even in patients with expanded indications, without compromising on post-transplant outcomes.
- 22 February 2024
- Published by Springer Nature in Current Hepatology Reports
- Vol. 23 (1) , 185-192
Open AccessIndication of Liver Transplant for HCC: Current Status and Future Directions
Purpose of Review: Liver transplantation remains the gold-standard treatment for cirrhotic patients with early stage, surgically unresectable hepatocellular carcinoma (HCC). In this review, we describe the current state of liver transplantation (LT) for HCC. Recent Findings: We review recent advances in expanded indications for LT, diagnostics with liquid biopsy and biomarkers, and the emerging role of immunotherapy in this patient population. Summary: Although the shortage of liver allografts necessitates a restrictive HCC selection policy, future advances in patient selection, liquid biopsy technologies and systemic therapies have the potential to improve access to liver transplantation even in patients with expanded indications, without compromising on post-transplant outcomes.